European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
Basel, 21 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Commission has approved Susvimo® (ranibizumab 100 mg/mL solution for injection) for the treatment of neovascular age-related macular degeneration (nAMD), a leading cause of vision loss in people over the age of 60. 5,6
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- REITIR: Breytingar á framkvæmdastjórn
- Déclaration agrégée de rachat d'actions propres du 14 septembre au 18 septembre 2026
- Kvika banki hf.: Reglubundin tilkynning um kaup á eigin bréfum í samræmi við endurkaupaáætlun og leiðrétting á fyrri tilkynningu um framkvæmd nýrrar endurkaupaáætlunar.
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →